
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is continuously expanding and diversifying their business, with recent acquisitions and an upcoming product launch. Their focus on the rapidly growing liquid biopsy and oncology diagnostics market, as well as their successful performance in the transplant industry, bodes well for the company's future growth. Additionally, their ambitious financial targets and successful RCM initiatives demonstrate a strong and strategic approach to driving profitability.
Bears say
CareDx is facing stiff competition and will need to generate sufficient revenue from its testing services in order to meet its growth expectations. However, the company expresses confidence in its commercial payer coverage and operational improvements, which may lead to an increase in ASPs and revenue. Despite these efforts, risks such as potential changes in technology and the need for inorganic growth opportunities may also impact the company's stock price.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares